/CEOS
CEOS Stock - Psykey, Inc.
Healthcare|Medical - Instruments & SuppliesOTC
$0.00+9.66%
+$0.00 (+9.66%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CEOS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.86
52W High$0.04
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $6.28M | $419,299 | $19,316 | N/A | N/A |
| Gross Profit | $6.26M | $415,976 | $11,265 | N/A | $-6 |
| Gross Margin | 99.6% | 99.2% | 58.3% | N/A | N/A |
| Operating Income | $-320,168 | $-797,504 | $-355,790 | $-331,660 | $-4,340 |
| Net Income | $-350,578 | $-1,323,951 | $-497,760 | $-343,699 | $-4,360 |
| Net Margin | -5.6% | -315.8% | -2576.9% | N/A | N/A |
| EPS | $-0.00 | $-0.00 | $-0.00 | $-0.00 | $0.00 |
Company Overview
Psykey, Inc. engages in the research, development, and commercialization of entheogenic, adaptogenic, and nootropic ingredients and formulations for its functional product lines to improve and optimize life. The company also engages in the development of technologies for the composition, bioavailability, and targeted delivery of entheogen-based therapeutics for the psychedelic market. Its retail products include functional mushroom coffees and teas, oral supplements, and single serve drink mixes. The company was formerly known as CeCors, Inc. and changed its name to Psykey, Inc. in August 2021. Psykey, Inc. was founded in 2002 and is based in Toronto, Canada.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
CEOSBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.00
Q3 2024
EPS Surprise History
Q3 22
No data
Q4 22
No data
Q1 23
No data
Q2 23
No data
Q3 23
No data
Q4 23
No data
Q2 24
No data
Q3 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 18, 2025 | — | — | — | — |
Q2 2025 | May 29, 2025 | — | — | — | — |
Q1 2025 | Feb 26, 2025 | — | — | — | — |
Q4 2024 | Nov 22, 2024 | — | — | — | — |
Q3 2024 | Aug 14, 2024 | — | $-0.00 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.00 | — | — |
Q4 2023 | Dec 30, 2023 | — | $-0.00 | — | — |
Q3 2023 | Sep 29, 2023 | — | $-0.00 | — | — |
Q2 2023 | Jun 29, 2023 | — | $-0.00 | — | — |
Q1 2023 | Mar 30, 2023 | — | $-0.00 | — | — |
Q4 2022 | Dec 30, 2022 | — | $-0.00 | — | — |
Q3 2022 | Sep 29, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 29, 2022 | — | $-0.00 | — | — |
Q1 2022 | Mar 30, 2022 | — | $-0.00 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.00 | — | — |
Q2 2021 | Jun 29, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 30, 2021 | — | $-0.00 | — | — |
Q3 2008 | Sep 30, 2008 | — | $-0.18 | — | — |
Q2 2008 | Jun 30, 2008 | — | $-0.04 | — | — |
Latest News
Loading news...
Frequently Asked Questions about CEOS
What is CEOS's current stock price?
Psykey, Inc. (CEOS) is currently trading at $0.00 per share. The stock has moved +9.66% today.
What is the analyst price target for CEOS?
No analyst price targets are currently available for this stock.
What sector is Psykey, Inc. in?
Psykey, Inc. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the OTC exchange.
What is CEOS's market cap?
Psykey, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does CEOS pay dividends?
No, Psykey, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorATTBF
Abattis Bioceuticals Corp.
$0.00
Mkt Cap: $0.0B
HADV
Health Advance Inc.
$0.00
Mkt Cap: $0.0B
HDVY
Health Discovery Corporation
$0.00
Mkt Cap: $0.0B
INSD
Instadose Pharma Corp.
$0.00
Mkt Cap: $0.0B
ISOLF
Isodiol International Inc.
$0.00
Mkt Cap: $0.0B
MEDVF
Medivolve Inc.
$0.00
Mkt Cap: $0.0B
NNBP
Nanobac Pharmaceuticals, Incorporated
$0.00
Mkt Cap: $0.0B
OWCP
OWC Pharmaceutical Research Corp.
$0.00
Mkt Cap: $0.0B
RBII
Rising BioSciences, Inc.
$0.00
Mkt Cap: $0.0B
RGDXQ
Response Genetics, Inc
$0.00
Mkt Cap: $0.0B
Explore stocks similar to CEOS for comparison